Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from BridgeBio Pharma ( (BBIO) ).
BridgeBio Pharma announced positive results from its Phase 3 CALIBRATE study of encaleret for treating autosomal dominant hypocalcemia type 1 (ADH1) on October 29, 2025. The study met all primary and key secondary endpoints, showing significant improvements in calcium and parathyroid hormone levels compared to conventional therapy. Encaleret was well-tolerated, with plans for a New Drug Application submission in 2026. The results suggest encaleret could become a new standard of care for ADH1, potentially impacting the lives of patients with this genetic condition.
The most recent analyst rating on (BBIO) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on BridgeBio Pharma stock, see the BBIO Stock Forecast page.
Spark’s Take on BBIO Stock
According to Spark, TipRanks’ AI Analyst, BBIO is a Neutral.
BridgeBio Pharma’s overall score is driven by strong earnings call performance and technical analysis indicators, despite challenges in financial stability and valuation. The company’s significant revenue growth and strong cash position are positive, but profitability issues and competitive pressures remain concerns.
To see Spark’s full report on BBIO stock, click here.
More about BridgeBio Pharma
BridgeBio Pharma, Inc. is a biopharmaceutical company focused on discovering, creating, testing, and delivering transformative medicines for genetic diseases. Founded in 2015, BridgeBio’s pipeline includes development programs ranging from early science to advanced clinical trials, with a commitment to applying advances in genetic medicine to help patients swiftly.
Average Trading Volume: 2,508,914
Technical Sentiment Signal: Buy
Current Market Cap: $12.33B
Learn more about BBIO stock on TipRanks’ Stock Analysis page.